Stay updated with breaking news from Coherui O. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Coherus to Acquire Surface Oncology - Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple... | June 16, 2023
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing... | June 16, 2023
–Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiplenext-generationimmunotherapies in clinical development funded bygrowing revenues –
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O pipeline: SRF388, currently in Phase 2 trials in lung and liver cancer, and SFR114, currently in a Phase 1/2 study as a monotherapy for advanced solid tumors. Coherus will issue shares at $5.2831 per s
Coherus BioSciences, Inc. (CHRS), announced on Friday that it has entered into a definitive merger agreement to acquire Surface Oncology Inc. (SURF). The acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs.